Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase TRIM52 is a member of the tripartite motif (TRIM) family of proteins, characterized by a RING domain that confers E3 ligase activity, and unique sequence features distinguishing it from other TRIM family members[1][2]. TRIM52 participates in the ubiquitin-proteasome system, targeting specific proteins—including itself—for degradation; it is unusually unstable and tightly regulated by multiple giant E3 ligases (such as BIRC6, HUWE1, and UBR4/KCMF1)[1][4]. TRIM52 maintains genomic DNA integrity by limiting the accumulation of topoisomerase 2 DNA adducts and acts to prevent cell cycle arrest via the p53 pathway—loss of TRIM52 results in increased DNA lesions, p53 activation, and decreased cell fitness[1]. It is upregulated in various cancers, where it contributes to cell proliferation and survival in a context-dependent manner[1][3]. In addition to its role in cell division and DNA repair, TRIM52 can act as an antiviral factor, such as inhibiting Japanese Encephalitis Virus replication by targeting viral proteins for degradation via the ubiquitin-proteasome system[2]. Its functions are essential in some cancer cell backgrounds and may represent a potential, although as-yet untargeted, therapeutic vulnerability[3].
Ubiquitination and proteasomal degradation of substrate proteins; mechanism for drugs would be inhibition or modulation of E3 ligase activity, but no drugs currently reported
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM52 (TRIM52).